Insight in the activity of the EPO-FGF23 signaling pathway in rare hereditary anemias with varies degrees of hemolysis and ineffective erythropoiesis and varying circulating EPO concentrations, will add to the understanding of the pathophysiology and bone complications of these diseases. This evidence concerns the gene FGF23 and anemia.